FindTrial
Sign In

Characteristic of ?dT-cell reconstitution and its association with the infection of Epstein-Barr virus post haploidentical hematopoietic stem cell transplantation

Characteristic of ?dT-cell reconstitution and its association with the infection of Epstein-Barr virus post haploidentical hematopoietic stem cell transplantation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-COC-16008052
Enrollment
Unknown
Registered
2016-03-03
Start date
2016-03-04
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic malignancies

Interventions

Case series:Nil

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients are 18 to 60 years of age with hematopoietic malignancy (including acute lymphoblastic leukemia,acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, chronic lymphocytic leukemia, and non-Hodgkin lymphoma). All patients are at complete remission status without relapse before transplantation. Patients are administrated with 10 mg/kg of ATG in conditioning regimens and receive allografts from an HLA-mismatched related donor.

Exclusion criteria

Exclusion criteria: 1. The patients with poor medical compliance; 2. Any other problems that patients could not participate this trial.

Design outcomes

Primary

MeasureTime frame
?dT-cell reconstitution after haploHSCT;—

Countries

China

Contacts

Public ContactLiu Jiangying
bjmuljy@163.com+86 13301001677

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026